Trials / Completed
CompletedNCT01673659
A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 mcg/Actuation Compared With Nasonex® Nasal Spray 50 mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,220 (actual)
- Sponsor
- Padagis LLC · Industry
- Sex
- All
- Age
- 12 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The objectives of this study is to demonstrate bioequivalence (comparable safety and efficacy) of the Test product to the Reference in the treatment of subjects seasonal allergic rhinitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mometasone furoate | |
| DRUG | Nasonex Nasal Spray | |
| DRUG | Placebo nasal spray |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2012-10-01
- Completion
- 2012-10-01
- First posted
- 2012-08-28
- Last updated
- 2021-10-22
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01673659. Inclusion in this directory is not an endorsement.